| Item | Content |
|---|---|
| Rating | Neutral (Hold) |
| Target Price | HK$21.5–24.4 (base-case fair value range, corresponding to 15–16.5x 2027E normalized earnings) |
| Current Price | HK$19.86 (close as of 2026-10-30) |
| Margin of Safety | Approx. +8% (vs. base-case range floor of HK$21.5); probability-weighted three-scenario expected value approx. HK$21.83 (+9.9%) |
| Time Horizon | 12 months |
| Market Cap / Share Capital | Approx. HK$76.88 billion (approx. RMB 65.18 billion); total shares 3.871 billion (2026-09-30) |
Mengniu's investment story has shifted from "impairment quagmire on the left side" to "cyclical recovery on the right side": raw milk prices turned positive year-over-year in July 2026 (first time in nearly 5 years), the company delivered 2026H1 revenue +7.8% and net profit attributable to shareholders +15.9%, full-year revenue guidance was raised to high single digits (per earnings call), the second growth curve of cheese/milk powder/fresh milk is scaling up, and impairment provisions plunged from RMB 2.32 billion to RMB 150 million. However, two restrained conclusions must come first: First, the incremental profit recovery in 2026 mainly comes from the swing of associate farms from losses to profits and impairment convergence; the core operating margin of 8.2% (-0.3pp YoY) has not improved, and the full-year normalized earnings guidance of RMB 4.1–4.5 billion implies a steep H2 ramp with nearly doubled YoY growth. Second, the current price of HK$19.86 has risen approx. 30% from the late-August low, corresponding to approx. 15.2x 2026E normalized PE in this report — roughly at parity with Yili's comparable forward PE (approx. 15.4x). The market has already paid for "recovery"; the odds have fallen from "undervalued" to "slightly positive." The core logic of the Neutral rating: upside +8%~+23% (base range HK$21.5–24.4) plus approx. 3.1% dividend yield, versus downside -30%~-20% (bear-case range HK$13.9–15.8); the decisive factor is the slope of milk price recovery in 2027 — a gradual rise (YoY ≤5%) means ASP recovery and expense convergence offset costs, a net positive; a sharp surge (>15%) means 2–3pp gross margin squeeze and net profit -13%~-33%. Weekly milk price reports and the 2027Q1 contractual milk price negotiations (December 2026–January 2027) are the most critical validation points.
Key evidence:
This report estimates 2026E normalized net profit attributable of RMB 4.1–4.5 billion (+25%~+37% YoY), 8–15% conservative vs. sell-side RMB 4.6–5.1 billion. The profit bridge decomposition requires clarity: FY2025 share of associates was -RMB 804 million; 2026E estimated associate share of +RMB 300–400 million based on Modern Dairy earnings of RMB 580–700 million × approx. 50% equity — this swing alone of +RMB 1.1–1.2 billion already exceeds the full-year net increment (+RMB 0.8–1.2 billion); excluding associates, core normalized YoY is approx. -10%~0%. Meanwhile, RMB 4.1–4.5 billion implies 2026H2 normalized earnings of RMB 1.3–1.7 billion, +98%~+159% YoY (2025H2 base only approx. RMB 650 million); delivery hinges on three assumptions without quantitative disclosure: no new major impairments in H2, effective tax rate falling from 31.5%, and Modern Dairy H2 profit ramp. If any one falls short, 2026E will slide toward the RMB 3.8–4.0 billion floor. 2026H1 net profit attributable already includes a one-time back tax of RMB 319.9 million (fully charged against attributable profit); excluding it, approx. RMB 2.81 billion.
Key evidence:
The price-side right turn itself is solidly evidenced (three consistent official monitoring sources), but with two caveats: First, supply clearance has not yet translated into output contraction — 2026Q1 national milk output +3.4% YoY, Jan–May dairy production +7.0%; herd destocking figures vary across sources (-550,000/-660,000/-830,000 head vs. peak); the 2026 supply-demand balance and expanding 2027 gap remain forecasts, not facts. Second, milk prices are a double-edged sword for Mengniu, not a one-way positive: raw milk and related ingredients account for roughly 40–50% of production costs; a ±10% milk price move, when unpassable, corresponds to ∓2~3pp gross margin and net profit -13%~-33% (backed out from the historical elasticity of +2.4pp gross margin when milk prices fell -13% in 2024, medium confidence), while hedging via ASP increases and promotional convergence has a 2–3 quarter lag — 2027 reporting is precisely the most vulnerable window. The slope tolerance band for this net-positive judgment: milk price YoY increase staying within 5%; if Huaxi's RMB 3.75 scenario (+22%) materializes and end-price increases are blocked (Nielsen June 2026 dairy all-channel sales still -8.6%), the net effect turns net negative.
Key evidence:
Three-layer value decomposition: asset layer book net assets per share (including goodwill) HK$12.39; hard floor after excluding goodwill and intangibles approx. HK$10–11 (rough estimate including brands); zero-growth EPV approx. HK$17.3/share (sustainable FCFE approx. RMB 5.4 billion, cost of equity 9.5%) — current price at approx. 15% premium to EPV; the portion paid for growth approx. 13% of current price (cheese/milk powder second curve + buyback optionality); reverse-solving the current price implies a perpetual growth rate of approx. 1.2% (sensitive to discount rate: ke ±1pp eliminates this conclusion), and implied 2026E attributable profit of RMB 3.83–4.35 billion, at the lower edge of the achievable range. Three scenarios: bear HK$13.9–15.8 (30% probability), base HK$21.5–24.4 (50%), bull HK$28.8–30.2 (20%); probability-weighted expected value approx. HK$21.83, +9.9% vs. current price. Dividend yield approx. 3.1% (FY2025 DPS RMB 0.520) provides a base return. Overall judgment: fairly valued, not undervalued — after the 10-30 jump, current price is only +0.7% from the most conservative sell-side anchor and +14% from the mean; the upside anchored to the end of August has been mostly digested.
Key evidence:
After approx. RMB 7.3 billion of one-off items over three years (Bellamy RMB 4.64 billion + FY2025 provisions RMB 2.32 billion + back tax RMB 320 million), new provisions in 2026H1 were only approx. RMB 150 million — the direction toward cleaner reporting is clear; but "clearance" is premature: entrusted loan net exposure of approx. RMB 1.06 billion in unresolved litigation, goodwill + other intangibles of RMB 16.4 billion (approx. 40% of attributable equity) still constitute a tail, and peer Yili also recorded impairments and back taxes in 2026Q2, suggesting some adjustments are industry-/policy-wide actions, not unique to Mengniu. Dividends have been well delivered: DPS RMB 0.489 → 0.509 → 0.520, three consecutive increases; 2025 total dividends RMB 2.017 billion (normalized payout ratio approx. 61%); buybacks in 2026 through end-October approx. HK$140–150 million, down approx. two-thirds vs. full-year 2025, deviating from the announced commitment in the three-year shareholder return plan — a substantive weakening signal of the shareholder return pillar — if monthly buybacks from Q4 onward do not recover to the HK$50 million range, this deviation will continue to cap the valuation ceiling.
| Metric (RMB 100 million) | FY2023 | FY2024 | FY2025 | 2026H1 (latest period) |
|---|---|---|---|---|
| Revenue | 986.24 | 886.75 | 822.45 | 447.95 (+7.8%) |
| Net profit attributable to shareholders | 48.09 | 1.05 | 15.45 | 23.72 (+15.9%) |
| Recurring net profit (this report's estimate, excluding impairments/back tax) | — | 44.35 | 32.85 | 28.05 |
| Gross margin | 37.2% | 39.6% | 39.9% | 40.8% (-0.9pp) |
| Net margin attributable | 4.9% | 0.1% | 1.9% | 5.3% |
| Operating cash flow | 83.49 | 83.32 | 87.51 | 24.93 (-11.1%) |
| Free cash flow (OCF − capex, estimated) | 41.78 | 47.48 | 62.56 | 20.01 |
| Cash + cash-like balances (period-end) | — | — | 366.0 | 437.17 (as of 2026-06-30) |
| Interest-bearing debt (period-end) | 374.11 | 346.37 | 253.89 | 307.23 (as of 2026-06-30) |
| Debt-to-asset ratio | 56.0% | 54.8% | 51.1% | 53.4% |
| Net debt/EBITDA | 2.63x | 3.88x | 1.91x | — |
| DPS (RMB) | 0.489 | 0.509 | 0.520 | No interim dividend |
Note: Mengniu does not disclose a Non-GAAP/adjusted net profit figure; "recurring net profit" is this report's estimate (reported attributable profit + impairment and other one-off items × 75% assumed tax rate added back; 2026H1 additionally adds back the RMB 319.9 million back tax), with an error band of approx. ±RMB 100–200 million. Cash-like balances = cash and bank balances + current/non-current other financial assets (including long-term deposits and wealth management products), same basis for both periods.
Reasons for metric changes (YoY ≥±20% summary): ① FY2024 attributable profit -97.8%: Bellamy goodwill and intangible asset impairments of RMB 4.64 billion (per management: prudently provisioned considering Bellamy's recent operations and market expectations), plus share of Modern Dairy losses of -RMB 827 million; ② FY2025 attributable profit +1378.9%: impairment provisions fell from RMB 4.64 billion to RMB 2.32 billion (idle production facilities RMB 431 million + financial assets such as receivables and entrusted loans RMB 1.889 billion), no goodwill/intangible impairments in the year; ③ FY2025 interest-bearing debt -26.7%: company explicitly stated "goal of lowering debt-to-equity ratio and repaying maturing foreign-currency debt"; ④ capex FY2025/2026H1 -30.4%/-51.2% YoY: capacity contraction cycle (annual capacity stable at approx. 14 million tonnes); announcement did not explain separately, consistent with restrained investment amid raw milk oversupply; ⑤ 2026H1 income tax +67.9% (effective rate 31.5%): one-time back tax payment of RMB 319.9 million (details not disclosed), directly reducing attributable profit by 13.5%; ⑥ 2026H1 share of associates -585 → +40 million RMB: Modern Dairy and other associates moving from losses toward profit.
Revenue of RMB 44.795 billion (+7.8%) marked the first strong positive-growth half-year since 2023, with all categories turning positive: liquid milk +5.2%, ice cream +8.5%, milk powder +22.8% (Bellamy +60%+), cheese +32.6% (Milkground revenue +28.7%). Attributable profit of RMB 2.372 billion (+15.9%) contained three divergence signals: gross margin 40.8%, -0.9pp YoY (2025H2 basic product price cuts + rising packaging/coconut oil/protein powder costs — first empirical sign that the cost dividend has peaked); selling expense ratio 27.6% (-0.3pp) but advertising and marketing spend +11.1% (new channel investment + Winter Olympics/World Cup marketing); one-time back tax of RMB 319.9 million depressed headline growth. Operating cash flow of RMB 2.493 billion (-11.1%) was mainly due to the back tax. Versus market expectations: BOCOM International, Jefferies, and others raised target prices in clusters after results (implying 2026E RMB 4.6–4.9 billion), but the stock fell approx. 6% cumulatively over three trading days after the announcement (HK$17.84) — against a backdrop of a +30% YTD gain, this was "good news delivered" profit-taking; the market's characterization of the results themselves was in line with expectations, with guidance slightly above; what truly drove the October re-rating was milk price data and policy catalysts, not the results themselves.
Business model: Asset-heavy FMCG manufacturing (full dairy value chain: owned + partner farm milk supply, 60+ plants, distribution-led channels); ambient white milk + yogurt contribute ~76–79% of revenue; one-time purchase demand, no subscription attributes; limited pricing power — the gross margin improvement in 2023–2025 (37.2%→39.9%) came almost entirely from lower raw milk prices rather than price hikes, and in 2026H1 core products were proactively repriced downward to meet competition. The high-margin hedge relies on mix upgrade (Telunsu, Daily Fresh milk growing 30%+).
Cash content of earnings: Cash conversion is Mengniu's hardest fundamental. OCF/recurring net profit: 1.74 in 2023, 1.88 in 2024, 2.66 in 2025; FCF/recurring net profit: 0.87 in 2023, 1.07 in 2024, 1.90 in 2025. 2025 OCF of RMB 8.75 billion hit an all-time high and free cash flow reached RMB 6.26 billion — revenue declined for two years while cash margins rose. Book profits were suppressed by impairments; true cash generation is far better than reported. 2026H1 OCF of RMB 2.49 billion (-11.1%) was dragged by back taxes, but still ≥ net profit attributable to shareholders.
Return on capital: FY2025 ROIC ~8.3% (NOPAT = operating profit RMB 6.56 billion × 75% ÷ (equity + net borrowings)), below the 15% moat threshold and barely above the 8% warning line, significantly below the historical center and Yili (ROE 21.4%) — a result of earnings pressure during the raw milk downturn. If earnings recover to the RMB 4.8 billion level in 2027, ROIC could return to 10%+, but the "duopoly = high returns" intuition does not hold in this cycle.
Capex quality: capex/depreciation 1.23 (2023) → 1.05 (2024) → 0.75 (2025), entering a "harvest phase" — capacity stable at ~14 million tonnes, utilization undisclosed; the company does not break out maintenance vs. growth capex, so structural shrinkage cannot be confirmed, but the RMB 431 million impairment on idle facilities in 2025 indicates some overcapacity.
Quality red flags: ① Upstream associates posted deep losses for two consecutive years (RMB -872 million in 2024, -804 million in 2025), dragging consolidated profits; the 2026H1 turnaround is cyclical, not structural; ② Goodwill + intangibles of RMB 16.4 billion (~40% of equity attributable to shareholders) stems from the Bellamy/Modern Dairy... — actually the Bellamy/Miaokelanduo acquisitions; Bellamy has been largely written off, while the Miaokelanduo chain (minority interests of RMB 6.66 billion) remains; ③ Minority interest profit in 2026H1 grew +19%, faster than attributable profit — part of the high-growth cheese profits do not accrue to the company's shareholders.
Words vs. deeds: partially delivered. Promise-delivery list: ① Payout ratio raised to 40% in 2023 → actual 40.0% (RMB 1.924 billion / 4.809 billion), delivered; ② FY2024 commitment to use profit excluding Bellamy and Modern Dairy impairments as the basis with a 45% payout → actual RMB 1.994 billion / ~4.43 billion ≈ 45%, delivered (note the base is an adjusted figure, not reported attributable profit); ③ 2025–2027 three-year shareholder return plan (steadily rising DPS + maintaining the 2024/2025 buyback pace) → dividend delivered in year one (RMB 0.520, +2.2%), buyback clearly scaled down (see C4), deviation. Operating margin guidance (+30–50bp per year): delivered in 2024 (6.3%→8.2%), missed in 2025 (8.0%, barely held amid revenue decline), 8.2% in 2026H1 (-0.3pp) — a pattern of "firm targets, discounted delivery."
Shareholder friendliness: neutral-leaning-friendly. Dividends have risen consecutively with a basis favorable to shareholders (payout on an adjusted basis even in low-profit years; FY2025 dividend of RMB 2.017 billion = 131% of reported attributable profit); cumulative buybacks and cancellations in 2023–2025 reduced total shares by 2.1% (3.955 → 3.871 billion shares); no dilutive issuance. Deductions: 2026 buyback scaled down against commitment; no interim dividend.
Risk signals: ① Impairments were concentrated in 2024 (the transition year from CEO Lu Minfang to Gao Fei); the one-off RMB 4.64 billion write-down carries "big bath" characteristics — although it did make the 2025-onward statements cleaner; ② Near-total executive turnover in the past two years (CEO 2024, CFO replaced by COFCO's Shen Xinwen in Aug 2025, Chairman Qing Lijun from COFCO); ~3,000 layoffs in 2025; strategic continuity depends on the new team; ③ COFCO's state-owned control provides credit and policy synergies, but industrial objectives (upstream production stability, milk procurement) may conflict with shareholder return maximization; ④ No signs of controlling-shareholder stake reductions or pledge risks.
| Segment | FY2025 revenue share | FY2025 YoY | 2026H1 share / YoY | Segment margin (FY2025→2026H1) | One-line business logic |
|---|---|---|---|---|---|
| Liquid milk | 79.0% | -11.1% | 75.6% / +5.2% | 7.2%→7.6% | Core base, driven by dual premium brands Telunsu + fresh milk; lower volume, stable price |
| Ice cream | 6.6% | +4.2% | 9.4% / +8.5% | 3.2%→17.3% (H1 seasonal peak) | Double-digit domestic growth + Aice #1 in Indonesia |
| Milk powder | 4.4% | +9.7% | 4.6% / +22.8% | 3.1%→10.5% | Recovery after Bellamy write-off (H1 +60%+) |
| Cheese | 6.4% | +21.9% | 7.0% / +32.6% | 4.1%→7.2% | Miaokelanduo #1 in market share; fastest-growing second curve |
| Others (raw materials trade) | 3.7% | +7.5% | 3.4% / +4.8% | Segment loss | Nai Lifang deep-processing investment phase |
The profit engine, unsurprisingly, is liquid milk (FY2025 segment profit ~RMB 4.69 billion, ~85% of total segment profit), but all growth momentum comes from cheese/milk powder/ice cream — three segments together under 20% of revenue. The 2026H1 liquid milk +5.2% recovery owes mainly to the low 2025H2 base and share consolidation. Segment margins vary widely (liquid milk 7–8% vs cheese 4–7% vs ice cream H1 17%), reflecting business structure: ambient white milk is a channel-and-brand scale business with thin unit margins; ice cream/cheese rely on single-product premium and B2B customization, but with weak scale effects and high seasonality. Mengniu does not disclose segment gross margins; the margins above are estimated as segment profit / segment revenue. Single-category dependence (liquid milk 76–79%) is a structural weakness: in a rising milk price environment its cost sensitivity exceeds the more diversified Yili (milk powder RMB 32.77 billion vs Mengniu ~RMB 3.6 billion).
Accounting red flags: ① Impairments concentrated in one period (severity: high) — a one-off RMB 4.64 billion charge 7 years after the Bellamy acquisition, in the management transition year, with no prior-year charges; ② Financial asset impairment spike (medium) — FY2025 receivables + entrusted loan impairments of RMB 1.89 billion, +408% YoY, far exceeding the revenue decline, pointing to funding chain risk among downstream customers and farms; ③ Volatile effective tax rate (medium) — 22.6%→77.5%→44.2%→31.5% (2023→2026H1), driven by non-deductible impairments, deferred tax reversals, and back taxes; net profit comparability is poor; ④ 2026H1 one-off back-tax charge of RMB 319.9 million fully charged against attributable profit (medium); cause (year/tax type/subsidiary) undisclosed; ⑤ Abrupt shift in inventory write-down cadence (low) — RMB 320 million in 2023 → 910 million in 2024 → 470 million in 2025, consistent with the price-war destocking rhythm.
Cross-period consistency: ① Operating profit smooth at 6.17→7.26→6.56 billion while attributable profit swings violently at 4.81→0.10→1.55 billion — one-off items dominate the statements; management's explanations align with the numbers (consistent); ② Selling expense ratio rising steadily at 25.5%→26.0%→26.3%→27.6%, advertising & marketing ratio 7.6%→11.1% — spending intensified during revenue decline, attributed by the company to new-channel marketing and major-event sponsorships (consistent, but the structural margin erosion warrants vigilance); ③ Gross margin attribution logic switched (inconsistent): FY2025 still claimed "gross margin up thanks to lower raw milk prices," while 2026H1 shifted to attributing declines to core-product price cuts and rising costs of packaging/coconut oil/protein powder — a caliber switch within the same downturn cycle, in essence indicating the cost dividend peaked in 2026. Overall judgment: the "dirtiness" of the statements is mainly in non-operating items; operating items (revenue-gross margin-expenses) are self-consistent across periods, with no systematic window dressing.
Current market data: Closing price HK$19.86 (2026-10-30), market cap HK$76.88 billion ≈ RMB 65.18 billion (at 1 CNY = 1.1796 HKD, 2026-10-30). PE(TTM) 34.8x (reported basis, distorted by impairments; percentile for reference only); this report's primary basis is normalized earnings: FY2025 adjusted 19.8x, 2026E 15.2x, 2027E 13.4x; PB 1.60x (50th percentile of the past 5 years, 97th percentile of the past year — the recovery rally has already run some distance); dividend yield 3.09%; EV/EBITDA(TTM) ~8.1x. Average daily turnover HK$300–600 million (0.4–0.8% of market cap), normal liquidity.
Peer comparison (as of 2026-10-30 close):
| Company | PE (basis) | PB | ROE | Growth | Key difference vs Mengniu |
|---|---|---|---|---|---|
| Mengniu Dairy | 15.2x (2026E normalized) | 1.60x | Normalized ~11–12% | 2026H1 +7.8% | Liquid milk dependence 76–79%, #1 in cheese |
| Yili Group | 15.4x (2026E forward) / 19.2x (TTM) | ~3.5x | 2025 ~21.4% | 2026Q1-3 +3.6% | 1.4x the scale, thicker milk powder/cold-drink second curves |
| China Feihe | 12.3x (TTM) | 0.87x | 7.7% | 2026H1 +2.3% | Single infant-formula category, pressured by birth rate |
| New Hope Dairy | 16.7x (TTM) | ~3.5x | 19.0% | 2026Q1-3 +5.0% | Regional leader in low-temperature fresh milk, rising net margin |
| Modern Dairy | ~10x (2026E) | — | Early recovery | 2026H1 turned profitable | Upstream shadow asset, Mengniu holds ~49.4% |
On a like-for-like basis, Mengniu and Yili's forward PEs are essentially at parity (15.2x vs 15.4x) — no valuation discount exists; the PB discount corresponds to the ROE gap (11–12% vs 21%) and liquid milk dependence. Pricing efficiency is reasonable.
Market-implied expectations: At 15–17x, the current price back-solves to implied 2026E attributable profit of RMB 3.83–4.35 billion (this report's estimate: RMB 4.1–4.5 billion; sell-side: RMB 4.6–4.9 billion — market expectations sit at the lower end of the achievable range, slightly conservative); Gordon back-solve implies a perpetual growth rate of ~1.2% (under ke=9.5%; a ±1pp shift in ke moves it to 0.2%–2.2%, a weak signal). In one sentence: the current price requires the company to lift normalized earnings just past RMB 4 billion in 2026 and stop there — modest recovery demands, but the market is no longer paying a discount for the recovery.
Three-tier value (EPV): Asset value (floor) — hard floor of ~HK$10–11 per share (tangible net assets ex-goodwill/intangibles of HK$7.38 + rough estimate of brand excess returns of HK$2.5–3.5), soft floor of HK$12.39 (including goodwill at book); zero-growth EPV ~HK$17.3/share (sustainable FCFE ~RMB 5.4 billion: base period OCF of RMB 8.75 billion, less normalized capex and taxes, with associates turning positive included — base is achieved FY2025, excluding planned growth); the current price of 19.86 is a ~15% premium to EPV, with the growth option accounting for ~13% of the current price — the market's payment for core-business recovery + second curves is not high, but the zero-growth floor sits 13% below the current price; the margin of safety comes from scenarios, not static value.
Three scenarios and odds (probabilities are this report's judgment):
| Scenario | Probability | Fair range | Core assumptions | vs. current price |
|---|---|---|---|---|
| Bear | 30% | HK$13.9–15.8 | Sharp milk price spike (+15%+) squeezing gross margin 2–3pp with price hikes blocked; liquid milk demand turning negative again; impairments recurring at RMB 800–1,200 million | -30%~-20% |
| Base | 50% | HK$21.5–24.4 | Gradual milk price rise (YoY ≤5%) + easing competition: 2026E RMB 4.1–4.5 billion → 2027E 4.7–4.85 billion, exit multiple 15–16.5x (anchor: Yili same-basis forward 15.4x parity + upper bound of own DDM-implied 12–15x) | +8%~+23% |
| Bull | 20% | HK$28.8–30.2 | Mild milk prices + markedly eased competition, gross margin 41.5%+, falling expense ratio; cheese/milk powder/Bellamy + Southeast Asia ice cream delivered; 2027E RMB 5.4–5.5 billion × 17.5–18x | +45%~+52% |
Probability-weighted expectation ~HK$21.83 (+9.9%, computed weighting scenario range midpoints). The current price sits in a transition band between the bear and base ranges — an intermediate state of "right recovery direction, but both H2 ramp-up and milk price slope discounted"; the distribution is near bimodal (gradual vs. sharp price rise). Odds are slightly positive (bull +45%~+52% vs bear -30%~-20%), but with no protection against the bear case. External anchors: most bearish sell-side is Morgan Stanley at HK$20 (short-term tactical view), consensus mean HK$22.7; this report's bear case is significantly below all sell-side targets — because the sell-side's uniform HK$21–26 buy ratings themselves constitute crowded expectations, and none models a sharp milk price spike; the bear case is built on independent stress assumptions and is not adjusted toward the uncovered sell-side floor.
Own earnings forecast (anchor for next reconciliation with results):
| Period | Revenue (RMB 100M) | Attributable net profit (RMB 100M, normalized) | Key assumptions |
|---|---|---|---|
| FY2026E | 873–885 (+6.0%~+7.6%) | 41–45 | H2 low base + early 2027 Spring Festival stocking; gross margin 40–40.5%; associates +RMB 300–400 million; tax rate 23–25% (no back taxes recurring) |
| FY2027E | 908–932 (+4%~+5.5%) | 46–51 | Gradual milk price rise, converging promotions; cheese +20–25%; Modern Dairy 2027E ~RMB 1.45 billion (Huayuan Securities) × ~49.4% stake |
Cross-check: management guides high-single-digit revenue growth (earnings call), sell-side 2026E RMB 4.6–5.1 billion — this report's revenue aligns with guidance midpoint, profit 8–15% more conservative, mainly due to H2 gross margin and tax rate assumptions.
Conclusion: fair value. Target range HK$21.5–24.4 (= base scenario fair value); the current price is ~8% below the base-case floor and ~15% above EPV — quality (cash conversion, duopoly position) and price (parity with Yili, 3.1% yield) broadly match; neither deeply undervalued nor a bubble. Anchoring basis for the base-case exit multiple of 15–16.5x: Yili same-basis forward 15.4x (parity) + the upper bound of own DDM (ke 9.5%, g 4.5–5.5%, payout 57%) implying 12–15x; the circular anchor of "current price is fair" is not used.
Market Size: China's dairy retail market is approximately RMB 659.0 billion (2024, Euromonitor retail sales basis, cited in sell-side reports; China Huajing Industrial Research Institute estimates about RMB 653.5 billion), down ~3.1% YoY—the industry has entered a mature phase of stock-based deepening after exhausting incremental penetration. Liquid milk retail sales posted a 2022–2024 CAGR of roughly -4.2% (Euromonitor); NielsenIQ dairy omni-channel sales fell -8.6% in 2025 and -4.7%/-9.7%/-8.6% in April/May/June 2026, marking the fourth consecutive year of adjustment. However, dairy output from above-scale enterprises rose +5.8% YoY in 2026H1, the best level since 2022—volume is recovering while value is shrinking, with pricing and mix as the main drags. Mainstream forecasts for the next 3–5 years point to low-single-digit growth (~2%–5%; Huajing's 2024→2026E implied CAGR is ~2.4%). Structural bright spots: low-temperature fresh milk, cheese, and functional products (high-protein, lactose-hydrolyzed) continue to outperform the broader market. By category: ambient white milk is a duopoly stock market (CR2 ~87%); pasteurized low-temperature fresh milk is about RMB 34.3 billion (Euromonitor 2019, with structural positive growth in recent years); cheese is about RMB 13.1 billion (Euromonitor 2021), recovering in 2025–2026 after the -25% shakeout in 2024H1; infant formula remains persistently dragged down by 2025 births of 7.92 million (-17%).
Value Chain and Value Distribution: Upstream raw milk (herd of ~5.77 million head at end-June 2026, Ministry of Agriculture and Rural Affairs monitoring) → midstream processing (Yili/Mengniu duopoly) → downstream distribution plus emerging retail. Value distribution in this cycle is severely imbalanced: dairy farming cumulatively lost about RMB 70 billion in 2023–2025, with spray-drying losses of about RMB 20 billion (National Dairy Technology System), while the midstream captured margin expansion through procurement bargaining power (Mengniu 37.2%→39.9%; Yili 34.6%)—gross profit primarily resides in the midstream brand tier. Mengniu holds strong bargaining power over upstream (controlling/stakes in the Modern Farming–Shengmu system locking in milk supply, together ~10.4% of national herd), but its bargaining power versus downstream has weakened against new channel giants like Sam's Club and snack mass retailers. As milk prices recover, some profits will flow back upstream: Mengniu recovers a portion through its ~49.4% equity-method stake in Modern Farming—the hedging edge of the "double-edged milk-price sword."
Supply-Demand and Competitive Landscape: Demand-side drivers are threefold—health orientation (high-protein/lactose-hydrolyzed), the shift to low-temperature products (structural positive growth in fresh milk), and deep processing (cheese/butter/whey; industry-wide daily processing capacity of 15,000 tonnes in 2026H1, annualized milk consumption of ~5 million tonnes, becoming the second demand engine for raw milk); demographics are a long-term headwind (births at record lows; childcare subsidies of RMB 3,600/child/year, ~RMB 100 billion in scale, provide a floor for infant formula). Supply-side has undergone deep destocking but this has not translated into output cuts: herd has been culled by a cumulative 550,000–830,000 head from peak (varying measures), but yield improvements kept 2026Q1 milk output up +3.4%—volume clearing lags herd clearing. Supply-demand should roughly balance in 2026 with the gap widening in 2027 (Huaxi Securities forecasts milk prices of RMB 3.75/kg for 2027–28)—a forecast, not established fact. Competitive landscape: ambient white milk CR2 ~87% (Yili 48%/Mengniu 39%, Huatai 2023 basis); low-temperature yogurt CR3 ~55%; infant formula CR2 ~37–39% (Feihe 19–20% vs Yili Jinlingguan 18.3% competing for #1; company-reported measures differ); cheese CR2 over 53% (Milkground >38% leading, Worldpanel/Euromonitor 2025). Entry barriers: national brands and channels (Kantar penetration 90%+), milk source control, cold chain, and infant formula formula registration. Price competition was intense in 2025 (terminal price cuts ~3%, promotions near 15%), clearly easing in 2026 as milk prices stabilized—management's framing: "milk price stabilization, consumption stabilization, structural upgrading."
Cycle and Regulation: The raw milk cycle has been declining since 2021Q3 for nearly 5 years, with the price inflection confirmed in mid-2026 (contract milk prices turning positive YoY, upstream farms collectively returning to profit)—characterized as "early right-side confirmation, gentle slope rather than V-shape." Leading indicators: loose-milk prices (RMB 2.5→2.8–3.1/kg, leading contract prices), daily spray-drying volumes (peak 10,000–20,000 tonnes→4,000 tonnes), replacement heifer ratio (over-culled), and the scissors gap between dairy output and raw milk output (+6.0% vs +2.4%). Regulation is net positive: the new national standard for sterilized milk (effective 2025-09-16, banning reconstituted milk and requiring raw milk as the sole ingredient) directly expands raw milk demand; the national childcare subsidy (announced 2025-07, retroactive to 2025-01-01, ~RMB 90 billion/year in central fiscal spending); expanded school milk program (102,000 schools and 31.34 million students covered in the 2024 school year). The industry is pushing to establish a raw milk price formation mechanism modeled on the US system, to correct the midstream–upstream profit distribution imbalance.
Company's Industry Position: China's #2 dairy company and one half of the duopoly (2025 revenue RMB 82.2 billion, about 71% of Yili's), a hybrid of "challenger + niche segment leader." Ambient white milk share ~39% vs Yili's 48%; 2025 liquid milk fell -11.1%, worse than Yili—the gap persists. Combined low-temperature share ~30%, ranking #1 (Nielsen 2020, an older measure). Premium fresh milk brand Daily Fresh is in the top tier (fresh milk segment +30%+ in 2026H1). Cheese is the only category where Mengniu is the clear #1 (Milkground retail share >38%, Worldpanel basis—consistent with the company's own claims). Ice cream ranks #2 domestically + #1 in Indonesia (Aice). Share trends: ambient under pressure; cheese/fresh milk/innovation businesses rising. Moats: the Sagyo super-SKU and national brand strength, milk source control (Modern Farming–Shengmu system), the Milkground cheese platform and B2B deep processing (Nailifang consumes ~320,000 tonnes of raw milk annually), and digitalization-driven cost reduction. Weaknesses: 76–79% revenue reliance on liquid milk; powder business is only ~1/9 of Yili's scale; the second growth curve remains small in absolute terms.
The decisive variable in dairy is not the demand narrative but raw milk prices, which affect Mengniu's P&L through four simultaneous pathways; the net effect depends on the slope:
Current Position and Assessment: Milk prices are up +1.3%~+2.0% YoY (September–October), in a "gentle rise zone"—the net effect of the four pathways is positive (mild gross margin pressure vs improvement across ASP/associates/impairments), which is exactly what the 2026H1 results show. Slope threshold: if YoY milk price gains stay ≤5%, net effect is positive; if they rise above +15% in 2027 (Huaxi's RMB 3.75/kg scenario) while industry retail sales (Nielsen basis) remain in negative growth (no room for price increases), Pathway 1 overwhelms Pathways 2–4, and the net effect flips to gross margin -2~3pp and net profit -13%~-33%—in that case Mengniu's rational response would be to accelerate mix upgrading and expense discipline, but the most vulnerable window for the financials would be precisely 2027. Monitoring tools: MOA weekly raw milk prices in main producing provinces (collected every Wednesday), provincial quarterly reference transaction prices, Modern Farming's cost per kg of milk (RMB 2.29/kg in 2026H1) and the milk price spread.
Overall: Neutral (Hold), confidence 0.55, 12-month horizon. Mengniu is a right-side trade of "genuine but diluted earnings repair, valuation already back at the mean": cash generation (FCF RMB 6.26 billion, OCF/recurring net profit 2.66x) and duopoly position are the core value, with a 3.1% dividend yield supporting holding returns. But 2026 profit growth comes mainly from associates' swings and impairment convergence, with core operating margin not improving; the near-doubling implied normalized YoY ramp in H2 needs validation; and the current price is at par with Yili on a like-for-like basis and at a 15% premium to zero-growth EPV—odds are slightly positive (probability-weighted +9.9%) but with no deep margin of safety. Strategy: hold primarily, do not chase; a pullback below HK$18 (~13.5x 2026E) with milk prices maintaining a gentle rise would improve risk/reward; a rise into the HK$21.5–24.4 base-case range would mean the undervaluation thesis has played out, warranting a reassessment of the case for further upside.
Risk Disclosure (formal summary): ① Sharp milk price surge squeezing gross margins (probability ~0.4, the most painful path); ② Demand recovery falsified—liquid milk growth falls below 5% or turns negative in 2026H2, with "recovery" repriced as "share replacement"; ③ Another RMB 1 billion-scale impairment (net entrusted loan exposure of RMB 1.06 billion in litigation; goodwill + intangibles RMB 16.4 billion); ④ Effective tax rate staying above 30% (cause of tax adjustments undisclosed; peers have made similar adjustments); ⑤ Weakened shareholder returns as buybacks keep shrinking; ⑥ Stock near one-year highs, southbound net selling in late October, short-selling ratio periodically near 20%—drawdown amplification risk in a crowded trade; ⑦ Food safety tail risk (low probability, high impact).
Monitoring Schedule: Key milestones over the next 12 months: weekly verification of milk price reports (from 2026-11), 2027Q1 provincial raw milk reference prices and annual contract price negotiations (2026-12 to 2027-01), Spring Festival sell-through (2026-12 to 2027-02), FY2026 annual results (expected around 2027-03-24, verifying high-single-digit guidance, final dividend, impairments, and tax rate), and monthly buyback pace. Falsification triggers: milk prices up >+5% YoY for 2 consecutive months, liquid milk revenue turning negative, recurrence of RMB 1 billion-scale impairments, or the stock falling below HK$15.8 (bear-case range).